Literature DB >> 19253234

Comparison of dose-related ocular side effects during systemic isotretinoin administration.

Tongabay Cumurcu1, Engin Sezer, Rasit Kilic, Yunus Bulut.   

Abstract

PURPOSE: To compare the effects of high- (Group 1) and low-dose (Group 2) isotretinoin treatments for acne vulgaris on lacrimal functions and other ocular complications.
METHODS: Twenty-six patients receiving high-dose (>0.5 mg/kg per day) systemic isotretinoin treatment and 25 patients treated with low-dose systemic isotretinoin (<0.5 mg/kg per day) underwent complete ophthalmologic assessment of both eyes before treatment, at days 45 and 90 of treatment, and 1 month after the completion of treatment, together with a microbiologic evaluation of conjunctival flora, tear film break-up time (BUT), and anesthetized Schirmer test of the right eye of each patient.
RESULTS: When the results of the anesthetized Schirmer test for Groups 1 and 2 were compared (pretreatment, days 45 and 90 of treatment, and 1 month after treatment), there was no statistically significant difference between the groups (p > 0.05). Although BUT did not differ significantly between the two groups before treatment (p >0.05), there was a statistically significant decrease in BUT in Group 1 when compared with Group 2 at days 45 and 90 of treatment (p <0.05). One month after the completion of treatment, there was no difference in BUT between the two groups (p >0.05). No difference in Staphylococcus aureus colonization was detected between the two groups at days 45 and 90 of treatment (p >0.05).
CONCLUSIONS: During systemic isotretinoin treatment, eye dryness was related to the dose used, at least during the period of treatment. Conversely, the rate of conjunctival S aureus colonization was unrelated to the dose of isotretinoin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253234     DOI: 10.1177/112067210901900204

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment.

Authors:  Cagatay Caglar; Engin Senel; Emine Sabancilar; Mustafa Durmus
Journal:  Int Ophthalmol       Date:  2016-05-18       Impact factor: 2.031

2.  Evaluation of corneal topography and biomechanical parameters after use of systemic isotretinoin in acne vulgaris.

Authors:  Yusuf Yildirim; Onur Olcucu; Alper Agca; Cengiz Alagoz; Ali Demircan; Abdurrahman Basci; Ahmet Demirok; Zekayi Kutlubay
Journal:  J Ophthalmol       Date:  2014-11-30       Impact factor: 1.909

3.  Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.

Authors:  Andrea L Zaenglein; Moise L Levy; Nicole S Stefanko; Latanya T Benjamin; Anna L Bruckner; Keith Choate; Brittany G Craiglow; John J DiGiovanna; Lawrence F Eichenfield; Peter Elias; Philip Fleckman; Leslie P Lawley; Richard A Lewis; Anne W Lucky; Erin F Mathes; Leonard M Milstone; Amy S Paller; Sonali S Patel; Dawn H Siegel; Joyce Teng; Sherry A Tanumihardjo; Lauren Thaxton; Mary L Williams
Journal:  Pediatr Dermatol       Date:  2020-11-10       Impact factor: 1.588

4.  Dermatologists' Knowledge and Attitude Toward Isotretinoin Ocular Side Effects in Egypt.

Authors:  Mohammed Elshafie; Azza Srour; Hussien El-Ansarey; Mostafa Abdel-Kader; Ibrahim Kabbash; Mohamed Mashaly
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-09-18

5.  Effect of retinoic acid on the nitrergic innervation of meibomian glands in rats.

Authors:  A Bolekova; D Kluchova; L Tomasova; N Hvizdosova
Journal:  Eur J Histochem       Date:  2012-11-30       Impact factor: 3.188

6.  Oral isotretinoin for acne.

Authors:  Caroline S Costa; Ediléia Bagatin; Ana Luiza C Martimbianco; Edina Mk da Silva; Marília M Lúcio; Parker Magin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2018-11-24

7.  Tolerance to systemic isotretinoin therapy in two patients using highly wettable contact lenses.

Authors:  Ayşegül Arman; D Deniz Demirseren; Gulsen Akoglu
Journal:  Case Rep Ophthalmol Med       Date:  2014-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.